- Home
- PRPL vs SKYE Comparison
PRPL vs SKYE Comparison
Compare PRPL & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPL
- SKYE
- Stock Information
- Founded
- PRPL 2010
- SKYE 2012
- Country
- PRPL United States
- SKYE United States
- Employees
- PRPL N/A
- SKYE N/A
- Industry
- PRPL Home Furnishings
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PRPL Consumer Discretionary
- SKYE Health Care
- Exchange
- PRPL Nasdaq
- SKYE Nasdaq
- Market Cap
- PRPL 125.6M
- SKYE 108.5M
- IPO Year
- PRPL N/A
- SKYE N/A
- Fundamental
- Price
- PRPL $1.07
- SKYE $3.91
- Analyst Decision
- PRPL Hold
- SKYE Buy
- Analyst Count
- PRPL 1
- SKYE 7
- Target Price
- PRPL $1.00
- SKYE $15.50
- AVG Volume (30 Days)
- PRPL 525.4K
- SKYE 314.0K
- Earning Date
- PRPL 11-03-2025
- SKYE 11-06-2025
- Dividend Yield
- PRPL N/A
- SKYE N/A
- EPS Growth
- PRPL N/A
- SKYE N/A
- EPS
- PRPL N/A
- SKYE N/A
- Revenue
- PRPL $456,844,000.00
- SKYE N/A
- Revenue This Year
- PRPL N/A
- SKYE N/A
- Revenue Next Year
- PRPL $11.87
- SKYE N/A
- P/E Ratio
- PRPL N/A
- SKYE N/A
- Revenue Growth
- PRPL N/A
- SKYE N/A
- 52 Week Low
- PRPL $0.56
- SKYE $1.14
- 52 Week High
- PRPL $1.29
- SKYE $6.01
- Technical
- Relative Strength Index (RSI)
- PRPL 53.58
- SKYE 54.00
- Support Level
- PRPL $1.01
- SKYE $3.71
- Resistance Level
- PRPL $1.11
- SKYE $4.55
- Average True Range (ATR)
- PRPL 0.06
- SKYE 0.31
- MACD
- PRPL -0.02
- SKYE 0.02
- Stochastic Oscillator
- PRPL 33.33
- SKYE 49.61
About PRPL Purple Innovation Inc.
Purple Innovation Inc is a comfort innovation company. The company designs, manufactures and sells a range of comfort technology offerings, including mattresses, a pillow, cushions, sheets, bed platforms and other products. The Company has one reportable segment that operates an omni-channel distribution which allows the Company to offer a seamless shopping experience to its customers across multiple sales channels. It sells its products through its direct-to-consumer e-commerce channels, retail brick-and-mortar wholesale partners, Purple showrooms, and third-party online retailers.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.